Recruiting

Observational Study

Sponsor:

University Health Network, Toronto

Code:

NCT05403177

Conditions

Breast Cancer

Colorectal Cancer

Pancreas Cancer

Kidney Cancer

Prostate Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients

Conditions

Breast Cancer

Colorectal Cancer

Pancreas Cancer

Kidney Cancer

Prostate Cancer

Study ID

NCT05403177

Start date

Jun 23, 2022

Status verified date

Jun, 2026

Completion date

Oct, 2030

Anticipated

Primary completion date

Apr, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy
2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:

1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)
2. Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization
3. Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.
4. Participating patients must agree to share their anonymized clinical and genomic data

Exclusion Criteria:

None.

Study Design

Enrollment

500 participants

Anticipated

Interventions and Outcome Measures

Arms

MOHCCN-O

Tumor tissue and blood samples will be collected from patients who are enrolled in this study but do not yet have the molecular profiling data that are required to meet the gold standard criteria. Data will include: pathology, clinical biomarkers, imaging diagnostic information, whole genome and epi-genome sequencing of tumor and normal tissues, immunoprofiling of tumor tissues and/or peripheral blood, bioinformatic annotation of molecular information, and longitudinal clinical and outcome data.

Primary outcome measure

  • Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

PM2C Central Office

416-946-4501MOHCCN@uhn.ca

Locations

Kingston Health Sciences Centre

Recruiting

Kingston, Ontario, Canada, K7L 2V7

Contacts

Principal Investigator:

Amber Simpson, PhD

Princess Margaret Cancer Centre

Recruiting

Toronto, Ontario, Canada, M5G2M9

Contacts

PM2C Central Office

416-946-4501MOHCCN@uhn.ca

Principal Investigator:

Lillian Siu, MD

More Information

Sponsor

University Health Network, Toronto

Last update posted

Jun 10, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University Health Network, Toronto on 2026-06-10.